Table 1A:
Baseline characteristics of the study patients (N=23)
| Patient and disease characteristics | Number |
|---|---|
| Age, median (range), years | 56 (28-69) |
| Female Sex | 11 (48%) |
| ECOG PS | |
| 0 | 14 (61%) |
| 1 | 9 (39%) |
| Primary tumor location | |
| Right | 1 (4%) |
| Left | 13 (57%) |
| Transverse | 2 (9%) |
| Rectal | 7 (30%) |
| Histological grade | |
| Moderately differentiated | 22 (96%) |
| Primary tumor stage, ≥T3 | 19 (83%) |
| Node positive primary | 13 (57%) |
| Synchronous metastases | 20 (87%) |
| Number of prior chemo lines, median (range) | 1 (1-3) |
| Extrahepatic disease | 4 (17%) |
| Pre-operative chemotherapy | |
| YesA | 18 (78%) |
| No | 5 (22%) |
| Pre-operative chemotherapy duration, median (range), months | 2 (1.5-6) |
| Pre-operative CEA, ng/mL, median (range) | 3 (0.9-65.7) |
| Tumor mutation | |
| POLE mutationB | 2 (9%) |
| BRAF mutation | 1 (4%) |
| KRAS mutation | 12 (52%) |
| TP53 mutation | 14 (61%) |
| APC mutation | 11 (48%) |
| MMR status | |
| pMMR | 21 (91%) |
| dMMR | 2 (9%) |
| Primary Tumor CMS (N=15) | |
| CMS1 | 0 (0%) |
| CMS2 | 7 (32%) |
| CMS3 | 4 (18%) |
| CMS4 | 4 (18%) |
A
Oxaliplatin-based in 12 (52%), irinotecan-based in 4 (17%) oxaliplatin + irinotecan based in 2 (9%); addition of bevacizumab in 15 (65%).
B
both POLE mutation patients were pMMR.